Hadlima Pushtouch is not covered on the Reformulary. Reformulary Group has selected specific adalimumab biosimilars to be covered: AMGEVITA, manufactured by Amgen, and HULIO, manufactured by Viatris. AMGEVITA and HULIO are considered preferred biosimilars as they offer the same clinical value at a lower net cost to the plan. AMGEVITA and HULIO require Special Authorization.
